Literature DB >> 2407301

N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.

M Lübbert1, J Mirro, C W Miller, J Kahan, G Isaac, G Kitchingman, R Mertelsmann, F Herrmann, F McCormick, H P Koeffler.   

Abstract

Ras genes can be altered by point mutations at critical portions of their coding regions to acquire transforming ability in vitro. These point mutations have been detected in a variety of human malignancies. However, their relevance for the clinical and biologic behavior of the subgroups of patients exhibiting these mutations in unclear. We analyzed 100 patients with childhood acute lymphocytic leukemias (ALLs) for point mutations of exons 1 and 2 of all three ras genes (H-ras, K-ras, and N-ras) by polymerase chain reaction and a combination of oligonucleotide hybridization and direct DNA sequencing. A 6% incidence of N-ras gene mutations was detected, all of which occurred at different nucleotides of codons 12 or 13 of N-ras. When correlating presence of ras mutations with the clinical and biologic features and the clinical outcome of these cases, a significantly higher risk for hematologic relapse (P = .01) and a trend toward a lower rate of complete remission (P = .07) was noted. The two groups did not differ in any of the known high-risk factors of ALL. These results suggest that presence of an N-ras mutation in children with ALL may be an independent predictor for worse clinical outcome and therefore may have therapeutic implications; further studies to confirm these findings are required because of the small number of patients with N-ras mutations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407301

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis.

Authors:  H Roelofs; M C Mostert; K Pompe; G Zafarana; M van Oorschot; R J van Gurp; A J Gillis; H Stoop; B Beverloo; J W Oosterhuis; C Bokemeyer; L H Looijenga
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

Authors:  A van Elsas; S F Zerp; S van der Flier; K M Krüse; C Aarnoudse; N K Hayward; D J Ruiter; P I Schrier
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

4.  Alterations of the p53, Rb and MDM2 genes in osteosarcoma.

Authors:  C W Miller; A Aslo; A Won; M Tan; B Lampkin; H P Koeffler
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

6.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

7.  Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling.

Authors:  C A Jamieson; K R Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors:  Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

9.  NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

Authors:  João B Oliveira; Nicolas Bidère; Julie E Niemela; Lixin Zheng; Keiko Sakai; Cynthia P Nix; Robert L Danner; Jennifer Barb; Peter J Munson; Jennifer M Puck; Janet Dale; Stephen E Straus; Thomas A Fleisher; Michael J Lenardo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

10.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Authors:  Gannie Tzoneva; Arianne Perez-Garcia; Zachary Carpenter; Hossein Khiabanian; Valeria Tosello; Maddalena Allegretta; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Jana Hof; Renate Kirschner-Schwabe; Teresa Palomero; Raul Rabadan; Adolfo Ferrando
Journal:  Nat Med       Date:  2013-02-03       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.